Patient Assessment After Possible Recalled Tyenne Exposure
FDA recall of a tocilizumab-aazg lot over possible glass particles prompts inventory quarantine, exposure verification, symptom assessment, documentation, and safety reporting when exposure cannot be excluded.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.